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Introduction: Although advanced gastric cancer has many limitations and response rate is marginal in chemotherapy.
Overexpression of human epidermal growth factor receptor 2(HER-2/neu) gene and its protein are associated with
increased cell division and a high rate of tumor growth and have been reported in several malignancies. Especially,
approximately 30% of breast cancer patients have overexpression of HER-2/neu protein and the overexpression
metastasize faster, induces resistance of the chemotherapy and down-regulate function of estrogen receptor.
Recombinant humanized anti-HER2 antibody (Herceptin) inhibits proliferation of HER-2/neu overexpressing tumor cells
and the use of that in combination in metastatic breast cancer have increased cytotoxicity of chemotherapeutic agents.
Methods: We evaluated the expression of HER-2/neu protein in gastric cell lines by FACS and then comparing the
cytotoxicity in chemotherapeutics (doxorubicin, cisplatin, paclitaxel, 5-FU) alone and in combination with Herceptin
according to the expression of HER-2/neu protein by MTT assay.
Results: 1. NCI-N87 (88%) gastric cancer cell line and SK-BR-3 (89%) breast cancer cell line with strong positivity of
HER-2/neu expression. YBC-2 (55%) and YBC-3 (48%) gastric cancer cell line with intermediated, weak positivity
respectively. Negative control U-87 MG (6%) brain cancer cell line were showed low expression of HER-2/neu. 2. Cell
growth was dose-dependently inhibited in HER-2/neu positive, control cell line SK-BR-3 by Herceptin treatment but not
observed in HER-2/neu negative control cell line U-87 MG. Effective growth inhibition was not observed in gastric
cancer cell lines with single treatment of Herceptin, all cell lines observed the dose-dependent growth inhibition to
chemotherapeutic agents (doxorubicin, cisplatin, paclitaxel and 5-FU). 3. Combination of Herceptin with doxorubicin
observed synergistic effects in all cancer cell lines except YBC-3, combination of Herceptin with cisplatin observed
NCI-N87 and SK-BR-3 and combination of Herceptin with paclitaxel observed synergistic effects in YBC-2. Combination
of Herceptin with 5-FU observed antagonistic effects in all cancer cell lines.
Conclusions: According to HER-2/neu expression level, effect of anti-cancer agents was observed differently in
combination of Herceptin with chemotherapeutic agents. This suggests that HER-2/neu expression level can be applied
standard of combination drug selection in combination of Herceptin With chemotherapeutic agents in gastric cancer.
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Since known that signal transduction pathways by growth
factor and its receptor play an impotent role in the car-
cinogenic process many studies are being conducted. The
HER-2/neu(erbB-2) protein, cell membrane glycoprotein,
is a growth factor receptor has the activity of receptor
tyrosine kinase [1]. HER2 has been frequently detected in
a wide range of human tumors. Normal cell secretion as-
sociated with HER-2/neu protein, but destruction of nor-
mal cells control causing protein overexpression, increases
the rate of cell division and growth induce precancerous
changes [2].
The HER-2/neu(erbB-2) gene which is located on hu-
man chromosome 17q21 [3], which has partial hom-
ology with the epidermal growth factor receptor(EGFR)
[4,5]. EGF (epidermal growth factor) receptor family has
the activity of receptor tyrosine kinase and consisted of
EGF receptor, c-erbB-2, c-erbB-3 and c-erbB-4 [6-8]. The
HER-2/neu oncoprotein, encodes a p185kD membrane
glycoprotein, receptor that is involved in the growth and
diffentiation of the tumor cells and 25 ~ 30% overex-
pressed in breast, ovarian and gastric carcinomas [9-12]
and the prognosis of these patients is poor [13-15].
Overexpression of HER-2/neu gene and it’s protein are
associated breast cancer patient’s prognosis and therapy
[16-18] and expression of HER-2/neu is strongly required
for tumor growth [19]. Those suggest that HER-2/neu in-
volved in the breast cancer occurrence, progression
and malignant and HER-2/neu overexpression is more
important than hormone receptors on the patients
with lymph node metastasis [9]. Therefore, these
therapeutic targets HER-2/neu protein drugs, recom-
binant humanized anti- HER-2/neu antibody - Herceptin,
effective in the treatment of breast cancer has been re-
ported [20].
Gastric cancer is the most prevalent cancer in the
China. The occurrence of gastric cancer is the multistep
carcinogenic process with variety genetic mutations.
HER-2 status is correlated with the depth of invasion,Figure 1 HER-2/neu expression in gastric cancer cell lines. The express
fluorescence-activated cell sorting analysis. The HER2/neu expression in thr
(weak ), 55% (medium) and 88% (strong), respectively. All groups of Isotype
control, SK-BR-3 of HER2/neu expression is 89%. U-87 MG showed lower exTNM stage, lymph node and distant metastasis of gastric
cancer [21]. HER-2/neu over-expression is related to
poor prognosis of gastric cancer but has a modest effect
on survival in gastric cancer as an independent progno-
sis factor [22]. Herceptin® as a cytostatic agent, the mono
therapy efficient of antitumor effects cannot be expected
but a lot of research is underway for combination ther-
apy with other anticancer drugs or biologic agents. How-
ever, still not accurately study of combination therapy of
Herceptin with anticancer drugs in gastric cell lines [13].
Therefore, in this study we investigate the effective com-
bination of Herceptin (Trastuzumab, Genentech Inc,
CA, USA) [23-25], targeting for HER-2/neu oncoprotein,
with anti-cancer drugs in gastric cancer cell lines, de-
pending on the HER-2/neu oncoprotein expression.
Materials and methods
Cells
Gastric cancer cell lines were used YBC-2, YBC-3 and
NCI-N 87 cell lines. The YBC-2 and YBC-3 cell lines
were established from intraperitoneal metastatic gastric
cancer by Department of Pathology, Yanbian University.
The NCI-N 87 cell line was established in the United
State by NCI (National Cancer Institute, CRL5822, USA).
The U-87 MG (ATCC, HTB14) brain tumor cell line and
SK-BR-3 (ATCC, HTB30) breast cancer cell line were used
for HER-2/neu protein expression positive and negative
control, respectively.
These cell line were cultured use minimum essential
media (MEM, GINCO BRL, Grand Island, NY, USA)
which is containing inactivated (at 56°C for 30 min) 10%
fetal bovine serum (FBS, GINCO BRL, Grand Island,
NY, USA), 100 unit/ml Penicillin and 0.1 mg/ml Strepto-
mycin. All culture incubations were performed in a hu-
midified 37°C, 5% CO2 incubator.
Drugs
Herceptin, Humanoid recombinant HER-2/neu antibody,
was from USA (Trastuzumab, 440 mg/20 ml, Genentechion of HER2/neu protein in all cancer cell lines were measured by
ee gastric cancer cell lines (YBC-2, YBC-3 and NCI-N87) were 48%
control were not more than 0.5% (data not showed). As the positive
pression of HER2/neu (6%) as negetive control.
Figure 2 Chemosensitivity of Herceptin® and four anti-cancer drugs in gastric cancer cell lines. In single use of Herceptin, the arrest of cell
growth was weak and IC50 was not detectable in vitro with stomach cancer cell line. In contrast, the four different anti-cancer drugs (doxorubincin,
cisplatin, paclitaxel and 5-FU) showed dose-dependent inhibition of cell growth and IC50 was detected.
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drugs, effect in gastric cancer, Adriamycin (Doxorubicin,
10 mg/5 ml), Cisplatin (Cisplatin, 10 mg/vial), Taxol (Pac-
litaxel, 30 mg/vial) and 5-FU (5-Flourouracil, 250 mg/
5 ml) were from China. When doing experiment each
drug was used diluted in cell culture media.Table 1 IC30 and IC50 of five anti-cancer agents against
YBC-2, YBC-3, NCI-N87, U-87 MG and SK-BR-3 cell lines
Anticancer agents Cell lines (IC30) μM
YBC-2 YBC-3 NCI-N87 SK-BR-3 U-87 MG
Herceptin 82.36 11.83 1326.72 0.02 289.09
Doxorubicin 0.6 0.76 0.01 0.03 0.07
Cisplatin 1.79 21 9.28 14.54 2.58
Paclitaxel 0.52 6.45 0.86 0.19 0.3
5-FU 33.11 0.22 4.11 148.75 5.51
Anticancer agents Cell lines (IC50) μM
YBC-2 YBC-3 NCI-N87 SK-BR-3 U-87 MG
Doxorubicin 2.93 2.31 0.07 0.1 0.29
Cisplatin 4.51 30.73 45.86 5.65 20.63
Paclitaxel 1.24 9.61 1.49 0.42 0.79
5-FU 752.04 4.74 119.61 753.42 46.58FACS analysis (HER-2/neu protein expression)
HER-2/neu(erbB-2) oncoprotein expression was done
using Fluorescence-activated Cell Sorter (FACS, Becton
Dickinson, U.S.A.) performed immunophenotyping in
cell surface. Culture cells (1 × 106) were harvested after
treat with trypsin-EDTA (GIBCOBRL, Grand Island, NY,
USA) and incubated with the primary antibody, Anti-
HER-2/neu antibody (Mouse Monoclonal Antibody,
LAB VISION, CA, USA), in a 1:200 dilution and 50 μl for
1 hour at 4°C. Stained cells were washed twice with cold
PBS. Staining and washing were performed in PBS (phos-
phate-buffer solution, pH 7.6 Ca++ Mg++ free, GIBCO
BRL, Grand Island, NY, USA) 2% FBS. After washing
twice a secondary FITC-antimouse antibody (Anti-Mouse
FITC-Conjugated antibody, Novocastra, USA) was used in
a 1:40 dilution, and 50 μl were incubated for 40 minute at
4°C, after then washed twice with cold PBS. After com-
pleting the staining, filtration cell solution were used
40 um nylon mesh obtain the single cell suspended matter
and doing analysis in the FACS.MTT assay (in vitro Herceptin and chemotherapeutic
agents sensitivity test in gastric cancer cell lines)
The MTT assay has been used for in vitro drug sensitivity
test in gastric cancer cell lines. MTT dye [3-(4,5-dimethyl
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide] is reduced
to formazan (a dark purple water insoluble compound) by
the succinate dehydrogenase system of active mitochon-
dria, and hence, specifically used to the optical density
(OD) of the wells was measured in an enzyme-linked im-
munosorbent assay (ELISA) reader Sunrise (TECAN) at
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viable cells. Cells were plated at 180 ul media of 1 × 104
cells per well in a 96 well multi-well plate and incubated
for 24 h at 37°C and 5% CO2.
For single drug sensitivity test, two methods were ap-
plied. First, Herceptin (4.625, 9.25, 18.5, 37 μM), doxo-
rubicin (0.0183, 0.183, 1.83, 18.3 μM), cisplatin (0.166,
1.666, 16.66, 166.6 μM), paclitaxel (0.0585, 0.585, 5.85,
58.5 μM) and 5-FU (38.43, 384.37, 3843.78, 38437.8 μM)
were diluted in 20 μl media and added to the plates and
incubated for 4 days. Control group were added only
media without the drugs and incubated same durations.
Second, the synergistic effect of the combination therapy
with a combination of Herceptin +Doxorubicin, Herceptin +
Cisplatin, Herceptin + Paclitaxel and Herceptin + 5- FU.Table 2 Calculated values for the Combination Index as a gro
Herceptin® and Doxorubicin in gastric cancer cell lines




DOX + HER 0.09 0.05
Diagnosis combined effect synergy synergy




DOX + HER 0.266 0.598
Diagnosis combined effect synergy synergy




DOX + HER 0.005 0.004
Diagnosis combined effect synergy synergy




DOX + HER 0.441 0.435
Diagnosis combined effect synergy synergy




DOX + HER 0.046 0.074
Diagnosis combined effect synergy synergy
DOX, Doxorubicin; HER, Herceptin.When combination treatment Herceptin and each antican-
cer drug performed sensitivity test, fixed molar concentration
percentage of both drugs, after then adding 50 μl MTT,
MTT was dissolved in phosphate buffer to the concentration
of 2 mg/μl, added to each well and incubated 4 hours more.
After removing the supernatant, placed 150 μl DMSO (Di-
methyl sulfoxide, Sigma, USA) in each well and gently shak-
ing about 15 minutes to dissolve the generated formazan.
The optical density (OD) of the wells was measured in an
enzyme-linked immunosorbent assay (ELISA) reader at 562
and 720 nm. The malignant cell survival was calculated by
the equation (OD of drug well- OD of blank well/mean OD
of control well - OD of blank well) × 100%. MTT assay was
performed and repeated three times for each dose of the
drug (5 well) the results were analyzed to obtain the average.wth inhibitory effect of combination treatment with
alue Parameter (μM)
ED90 Dm m r
2.93 0.54 0.98
1201.02 0.32 0.91
0.03 0.25 0.74 0.96
synergy
alue Parameter (μM)
ED90 Dm m r
2.310 0.768 0.946
46.063 0.623 0.970
1.377 0.406 0.469 0.925
antagonism
alue Parameter (μM)
ED90 Dm m r
0.070 0.398 0.864
113350 0.191 0.635
0.003 0.000 0.437 0.995
synergy
alue Parameter (μM)
ED90 Dm m r
0.295 0.620 0.997
1845.5 0.457 0.860
0.448 0.101 0.589 0.992
synergy
alue Parameter (μM)
ED90 Dm m r
0.103 0.832 0.998
1424000 0.046 0.435
0.117 0.005 0.616 0.985
synergy
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CI (Combination index) was obtained by the formula of
Chou-Talalay, was calculated from the value of IC50
(Dm) compared the efficacy and capacity curve (the m
value). Classic formula of the Isobologram (CI = 1) was
as follows.
CI ¼ Dð Þ1= Dxð Þ1 þ Dð Þ2= Dxð Þ2
Denominator of (Dx)1 and (Dx)2 were indicate the per-
centage cytotoxicity of when treated with single drug
alone; numerator of (D)1 and (D)2 were indicate the per-
centage cytotoxicity of when treated with both drugs.
Dx ¼ Dm fa= 1−fað Þ1m
Dm is the median-effect dose (IC50), this calculated by
median-effect plot of the X-intercept from the antilog.
X ¼ log Dð Þversus Y ¼ logfa= 1−fað Þ
m is the slope of the median-effect plot. Multiple drug
effect analysis using Calcusyn (Biosoft, Cambridge, UK),
were calculated values of m, Dm, Dx, and CI. (Dx) 1 and
(Dx) 2 were calculated using the Chou-Talalay median-
effect formula. CI <1, CI = 1, CI > 1 were called syner-
gism, summation, and antagonism effects respectively.Figure 3 Combination Index as a growth inhibitory effect of combina
combination of Herceptin and doxorubincin treatment, the synergetic effec
b. In the combination of herceptin and cisplatin, the synergetic effects wer
the inhibitory effects were observed in YBC-2 and U-87 MG cell lines (CI > 1
cell lines, the inhibitory effects were observed (CI > 1), however, in YBC-3 cell
lines, the effects were different depends on the dose of the drugs. d. In the c
in all of the cell lines (CI > 1).Statistical evaluation
Statistical analyses of the data were performed using
the two-tailed Student t-test (SPSS 13.0 software; SPSS,
Chicago, IL). p values less than 0.05 were considered
statistically significant. Analysis of variance (ANOVA)
was used for multiple group comparisons to determine
the potential antitumor effects between groups.Results
HER-2/neu expression in gastric cancer cell lines by FACS
The expression of HER2/neu protein was analysed in
three different stomach cancer cell lines (YBC-2, YBC-3
and NCI-N87). The expression of this proteinis 48%
(weak), 55% (medium) and 88% (strong) in YBC-2, YBC-
3 and NCI-N87, respectively. The expression of this pro-
tein was 89% in positive breast cancer cell line SK-BR-3,
and 6% in negative brain tumor cell line U-87 MG
(Figure 1).The sensitivity of stomach cancer cell line to Herceptin
and anti-cancer drug and the analysis of sensitivity to
single drug treatment in vitro
In single use of Herceptin, the arrest of cell growth was
weak and IC50 was not detectable in vitro with stomach
cancer cell line (Figure 2). In contrast, the four different
anti-cancer drugs (doxorubincin, cisplatin, paclitaxel andtion treatment with Herceptin® and anti-cancer agents. a. In the
t was observed in YBC-2 and NCI-N87 cells, but not in YBC-3 cell line.
e observed in SK-BR-3, NCI-N87 and YBC-3 cell lines (CI < 1). However,
). c. The treatment of Herceptin and paclitaxel, in YBC-3 and U-87 MG
line, the synergetic effect was observed (CI < 1). In SK-BR-3 and NCI-87 cell
ombination of Herceptin and 5-FU, the inhibitory effects were observed
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and IC50 was detected (Table 1, Figure 2).
The effect of the combination of Herceptin and
anti-cancer drugs
In the combination of Herceptin and doxorubincin treat-
ment, the synergetic effect was observed in YBC-2 and
NCI-N87 cells, but not in YBC-3 cell line which has weak
expression of HER2/neu protein (Table 2, Figure 3a, P <
0.05). In the combination of herceptin and cisplatin, the
synergetic effects were observed in SK-BR-3, NCI-N87 and
YBC-3 cell lines (CI < 1, P < 0.05). However, the inhibitory
effects were observed in YBC-2 and U-87 MG cell lines
(Combination Index > 1, P < 0.05) (Table 3, Figure 3b). The
treatment of Herceptin and paclitaxel, in YBC-3 and U-87Table 3 Calculated values for the Combination Index as a gro
Herceptin® and Cisplatin in gastric cancer cell lines




CDDP + HER 1.375 2.707
Diagnosis combined effect antagonism antagonism




CDDP + HER 0.274 0.110
Diagnosis combined effect synergy synergy




CDDP + HER 0.03 0.01
Diagnosis combined effect synergy synergy




CDDP + HER 9.18 9.85
Diagnosis combined effect antagonism antagonism




CDDP + HER 0 0
Diagnosis combined effect synergy synergy
CDDP, Cisplatin; HER, Herceptin.MG cell lines, the inhibitory effects were observed (CI > 1),
however, in YBC-3 cell line, the synergetic effect was ob-
served (CI < 1, P < 0.05). In SK-BR-3 and NCI-87 cell lines,
the effects were different depends on the dose of the drugs
(Table 4, Figure 3c). In the combination of Herceptin and
5-FU, the inhibitory effects were observed in all of the cell
lines (CI > 1, P < 0.05) (Table 5, Figure 3d).
Discussion
The overexpression of the growth factors or the receptors
of the growth factors in the signaling pathways, will
not only highly affect cell growth but also induce tumori-
genesis. Pro-oncogenes play important roles during cell
growth, development and differentiation. They also in-
volved in the function of the growth factors and theirwth inhibitory effect of combination treatment with
alue Parameter (μM)
ED90 Dm m r
4.512 0.921 0.882
1201.0 0.316 0.915
5.337 2.232 0.587 0.965
antagonism
alue Parameter (μM)
ED90 Dm m r
30.733 2.227 0.929
46.063 0.623 0.970
0.054 12.091 1.472 0.998
synergy
alue Parameter (μM)
ED90 Dm m r
45.86 0.53 0.93
1.13E + 05 0.19 0.63
0.01 0.83 0.88 0.96
synergy
alue Parameter (μM)
ED90 Dm m r
5.65 1.08 0.98
1845.53 0.46 0.86
10.58 2.56 1.01 0.99
antagonism
alue Parameter (μM)
ED90 Dm m r
20.63 2.42 0.94
1.42E + 06 0.05 0.43
0 1.45 1.44 0.99
synergy
Table 4 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with
Herceptin® and Paclitaxel in gastric cancer cell lines
YBC-2 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX 1.24 0.98 0.9
HER 1201.02 0.32 0.92
TAX + HER 6.03 14.77 36.21 0.85 0.54 0.82
Diagnosis combined effect antagonism antagonism antagonism
YBC-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX 9.609 2.129 0.940
HER 46.063 0.623 0.970
TAX + HER 0.225 0.172 0.185 7.010 1.220 0.889
Diagnosis combined effect synergy synergy synergy
NCI-N87 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX 1.49 1.56 0.96
HER 113350 0.19 0.63
TAX + HER 1747.94 0.81 0 858.42 −0.16 0.90
Diagnosis combined effect antagonism synergy synergy
U-87 MG Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX 0.79 0.89 0.87
HER 1845.53 0.46 0.86
TAX + HER 361.02 1571.47 6840.35 1.27 0.41 0.89
Diagnosis combined effect antagonism antagonism antagonism
SK-BR-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
TAX 0.42 1.11 0.96
HER 1.42E + 06 0.05 0.43
TAX + HER 0.05 0.24 1.12 0 0.44 0.88
Diagnosis combined effect synergy synergy antagonism
TAX, Paclitaxel; HER, Herceptin.
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normal cell growth and induce the cells become tumor
cells. The overexpression of receptors of growth factors,
such as FGF-5, TGF-a, EGF, will induce tumorigenesis.
After HER-2/neu protein was first discovered in breast
cancer cells [4], this protein has been actively studied in
breast cancer field. In about 30% of total breast cancer
patients, Her-2/neu is overexpressed. Many in vitro and
in vivo studies have shown that the increased level of
HER2 was associated with the early stage breast cancer
[26], recurrence rates, cancer metastasis and the de-
creased efficiency of hormone-based therapy [5,27].
HER-2 has been considered as factor for poor prognosis.
HER-2 oncogene is located on the chromosome seven-
teen q21 and structurally has close relationship withEGFR gene which is locate in chrosome seven and v-erbB
oncogene. Point mutation of HER-2 in transmembrane
domain forms 4.8 kb mRNA and 185 Kd glycoprotein
which belongs to tyrosine kinases.
Overexpression of HER-2 protein is not discovered in
normal tissues. In contrast, it is overexpressed in pri-
mary and metastatic cancer tissues which have been
considered as the target of therapy. HER-2/neu might be
a useful target for immunotherapy in colorectal carcin-
oma, anti-HER2 anti-CD3 BsAb exerting clear anti-
tumor effects [28]. In vitro and in vivo studies showed
that inhibition of HER-2 with anti-HER2 antibody
showed high toxicity to breast cancer cells [29]. Hercep-
tin is anti-HER2 antibody. It was developed as the com-
bination of human immunoglobulin with murine antigen
Table 5 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with
Herceptin® and 5-FU in gastric cancer cell lines
YBC-2 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU 752.04 0.27 0.94
HER 1201.02 0.32 0.91
5-FU + HER 8060.81 1620.97 325.97 285.29 0.45 1
Diagnosis combined effect Antagonism Antagonism Antagonism
YBC-3 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU 4.739 0.279 0.920
HER 46.063 0.623 0.970
5-FU + HER 75054 2.89E + 05 1.13E +06 71.077 0.207 0.928
Diagnosis combined effect antagonism antagonism antagonism
NCI-N87 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU 119.61 0.25 0.97
HER 1.1E + 05 0.19 0.63
5-FU + HER 1.9E + 17 3.2E + 02 5.3E +29 3.7E + 14 −0.02 0.87
Diagnosis combined effect antagonism antagonism antagonism
U-87 MG Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU 46.58 0.4 0.84
HER 1845.53 0.46 0.86
5-FU + HER 25540 4940.8 955.81 6.48 0.98 1
Diagnosis combined effect antagonism antagonism antagonism
SK-BR-3 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU 753.42 0.52 0.93
HER 1.42E + 06 0.05 0.43
5-FU + HER 226.52 173.36 132.68 488.15 0.6 0.93
Diagnosis combined effect antagonism antagonism antagonism
DOX, Doxorubicin; HER, Herceptin; CI Combination index.
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trial with metastic breast cancer patients showed that
21% efficacy and also increased the efficiency of antican-
cer drugs [30]. Park et al. reported that HER-2 gene has
close relationship with stomach cancer formation and
Yonemura et al. suggested that overexpression of HER2
is related to poor prognosis in stomach cancer patients
and anti-HER2 antibody may be an essential drug for
the therapy [31].
The most efficient therapy of the stomach cancer is
surgery. However, recurrence or metastatic recurrence
has been found in 80% patients after surgery, alternative
anti-cancer therapy or induced anti-cancer therapy is ne-
cessary for the patients after surgery. However, the
chemical drugs which have been used in these patients,
such as 5-FU, doxorubincin, cisplatin, mitomycin andpaclitaxel, showed only 15-30% efficiency, it is essential
to understand the mechanism of stomach cancer forma-
tion and develop a new therapy.
In this study, first we analyzed the expression of Her-2
in three stomach cancer cell lines (YBC-2, YBC-3, NCI-
N87) and found that HER2 is highly expressed in NCI-
N87. In YBC-3, the expression of HER2 is much weaker
and in YBC-2, the expression of this protein is higher
than that in YBC-2 but lower than that in NCI-N87. To
more clearly analyze the expression of HER-2 in the
cells, flow cytometry was used. Doxorubin, cisplatin,
paclitaxel and 5-FU four different anticancer drugs were
commonly used in chemotherapy and their effects are
relatively effective and these compounds have synergic
effects when combined with Herceptin in breast cancer
therapy.
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IC40 was observed. This can be explained that the half-
life of Herceptin is short (72 hrs), the compound was de-
graded and not present anymore during MTT assay
(96 hrs). Also Herceptin is a cytostatic agent which binds
to the growth factor receptor. Although it inhibits HER-2
mediated cell growth pathway, it may induce cell growth
through other pathways which there was no difference
after increase the dose of compound. In our work, the
maximum dose of Herceptin was used and this dose was
known effective in breast cancer treatment.
It was found that all of the four compounds could in-
hibit the growth of cells dose-dependently in SK-BR-3
cells where HER-2 is highly expressed. This data con-
firmed the relationship between HER-2 expression and
doxorubicin efficiency. However, cisplatin didn’t dose-
dependently inhibit cell growth in HER-2 highly ex-
pressed NCI-N87 stomach cancer cells. In contrast, it
inhibited cell growth in other cell lines. Different from
cisplatin and Herceptin, paclitaxel inhibited the growth
of cells independent of HER-2 expression. Yu et al. [32].
showed that the cells developed resistant to paclitaxel
and Baselga et al. [33]. Showed drugs inhibition need
more detailed research is needed.
The synergism, summation and antagonism among
Herceptin and other anti-cancer compound is not de-
pends on the expression of HER-2 or the change of
phosphorylation [20]. Herceptin single drug has no cyto-
toxicity in cancer cell in vitro. But by blocking its down-
stream signaling pathways, to inhibit the cell survival or
drug resistance gene expression to achieve synergistic ef-
fect in combination therapy. According to previous re-
ports, pretreatment of doxorubicin can increase the
expression of EGFR or TGF-α in cells, therefore the
combined with anti -EGFR antibody treatment maybe
achieve synergy effect in most of cell lines including
U87MG cells even that has no or little HER2 expression.
This needs forther studies to confirm. Cisplatin induces
DNA adduct and inhibits cell growth. It disrupts DNA
replication during cell division. If pretreatment the cells
with anti-HER2 antibody, the repair efficiency of the
DNA breaks which induced by cisplatin is decreased
[25]. Paclitaxel also showed dose-dependent efficiency.
Chang et al. [31]. showed that paclitaxel causes G2/M
phase arrest and also induces cell toxicity in G0/G1
phase [34]. When combination with herceptin, the effect
of paclitaxel on G2/M phase arrest was more efficient
and increased the toxicity to the cells. Also Herceptin
treatment increased G0/G1 phase cells [35] which in-
creased the sensitivity of the cells to paclitaxel treat-
ment. In the treatment of Herceptin and 5-FU, all the
cells showed resistant effect (CI > 1).
In conclusion, in different type of stomach cancer cell
lines, the expression of HER-2 protein is different, sodifferent anti-cancer compounds (doxorubicin, cisplatin,
paclitaxel and 5-FU) should be used depends on the ex-
pression of HER-2. This suggests that HER-2/neu ex-
pression level can be applied to standard for drug
selection in combination of Herceptin® with chemothera-
peutic agents in gastric cancer.
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